Molecular Partners AG (MOLN) Actualités

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing...

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action 

Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of...

Life Science Cares Launches in Switzerland

ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce...

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG...

Molecular Partners Publishes Invitation to Annual General Meeting 2024

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG...

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of...

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Collaboration leverages lead-based (212Pb) alpha emitter expertise and supply of Orano Med with Molecular...

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG...

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed...